What is the recommended management for severe alcoholic hepatitis?

Management of Severe Alcoholic Hepatitis

For patients with severe alcoholic hepatitis (mDF ≥32 or MELD >20), prednisolone 40 mg daily for 28 days is the first-line treatment after ruling out active infection, and treatment response must be assessed at day 7 using the Lille score to determine whether to continue or stop therapy. 1, 2

Initial Assessment and Severity Stratification

Before initiating any specific therapy, you must:

• Calculate disease severity using mDF (Maddrey Discriminant Function) ≥32, MELD score >20, GAHS ≥9, or presence of hepatic encephalopathy to identify severe disease 1, 3
• Screen for infection systematically with blood cultures, urine cultures, and ascitic fluid analysis (if ascites present) regardless of fever, as infection occurs in 20-30% on admission and develops in another 25% during treatment 2, 4
• Exclude contraindications to corticosteroids: active gastrointestinal bleeding, renal failure, pancreatitis, uncontrolled infection, hepatitis B, or tuberculosis 1

Treatment Algorithm for Severe Alcoholic Hepatitis

Step 1: First-Line Therapy (If No Contraindications)

Prednisolone 40 mg/day orally (or methylprednisolone 32 mg/day) for 28 days 1, 3, 2

• This improves 28-day survival (84.6% vs 65.1% placebo) but does not improve long-term survival beyond 3 months 1
• The benefit is modest and limited to short-term outcomes 5

Step 2: Early Response Assessment at Day 7

Calculate the Lille score on day 7 of treatment 1, 2, 1:

• Lille score <0.45: Continue prednisolone for full 28 days (6-month survival 85%)
• Lille score 0.45-0.56: Consider case-by-case continuation; these are partial responders with intermediate outcomes 2
• Lille score ≥0.56: STOP corticosteroids immediately - these are null responders with 6-month survival of only 25% and increased infection risk 1

Critical pitfall: Continuing steroids in null responders (Lille ≥0.56) increases infection risk without survival benefit. Discontinue immediately and consider rescue therapy 1.

Step 3: Alternative Therapy (If Steroids Contraindicated)

Pentoxifylline 400 mg orally three times daily for 28 days 1, 3, 1

• Reduces 28-day mortality (24.5% vs 46.1% placebo), primarily by decreasing hepatorenal syndrome (50% vs 92% of deaths) 1
• However, pentoxifylline is inferior to corticosteroids (1-month survival 74.5% vs 87.0%) 1
• Note: Recent evidence from the 2018 EASL guidelines and 2022 French guidelines suggests pentoxifylline efficacy is very weak and can no longer be strongly recommended 4, though earlier 2013 guidelines still list it as an alternative 1

Do NOT use:

• Combination therapy (steroids + pentoxifylline): No survival benefit at 4 weeks or 6 months 1
• Pentoxifylline as rescue therapy for steroid non-responders: 2-month survival identical to continuing steroids (35.5% vs 31.0%) 1

Step 4: Adjunctive Therapy

Consider N-acetylcysteine addition to corticosteroids 1:

• Reduces 1-month mortality (8% vs 24% with steroids alone)
• Decreases hepatorenal syndrome deaths (9% vs 22%)
• However, no improvement in 3-month or 6-month survival
• The evidence requires further validation, but the short-term benefit may justify use in severe cases

Step 5: Rescue Therapy for Non-Responders

For patients with Lille score ≥0.56 (null responders) 1:

• Consider liver transplantation - survival significantly higher with transplantation than continued medical therapy alone 1
• Evaluate using combined MELD and Lille scores for optimal risk stratification 2
• Traditional 6-month abstinence requirement is being reconsidered for severe cases 1

Therapies That Should NOT Be Used

Anti-TNF agents (infliximab, etanercept): Higher mortality and serious infection rates 1, 4

Essential Supportive Care

Nutritional Support (Critical Component)

• Protein: 1.2-1.5 g/kg/day
• Calories: 35-40 kcal/kg/day (increase to 40 kcal/kg in critically ill)
• Route: Enteral feeding preferred; use feeding tube if patient cannot eat due to anorexia or encephalopathy 3, 1, 5
• Supplement: Thiamine, vitamin B12, folic acid, pyridoxine, vitamin A, vitamin D, and zinc 1

Infection Surveillance

• Monitor closely throughout hospitalization, especially in steroid-treated patients 2, 4
• Repeat cultures if clinical deterioration occurs
• Infection developing during corticosteroid treatment increases mortality by 30% at 2 months 4

Renal Protection

• Avoid nephrotoxic drugs including diuretics when possible, as acute kidney injury is an early manifestation of multi-organ failure 5
• Monitor for hepatorenal syndrome development

Alcohol Abstinence: The Foundation

Alcohol abstinence is the single most important treatment and must be addressed immediately 1, 3, 1. While 3-month survival relates primarily to hepatitis severity, long-term outcomes (beyond 3 months) depend almost entirely on achieving abstinence 2. Involve addiction specialists early in hospitalization 5.

Long-Term Management

• 5-year survival with abstinence: 80% in treatment responders
• 5-year survival with relapse: 50% in treatment responders 2
• Pharmacologic treatment for alcohol use disorder should be initiated to maintain abstinence 6
• Evaluate for liver transplantation in appropriate candidates with decompensated cirrhosis 1

Key Clinical Pitfalls to Avoid

1. Starting steroids without infection screening - Always culture first 2, 5
2. Continuing steroids beyond day 7 without Lille score assessment - You may be causing harm in non-responders 1, 2, 1
3. Using combination therapy (steroids + pentoxifylline) - No added benefit 1
4. Switching to pentoxifylline in steroid non-responders - Ineffective as rescue 1
5. Inadequate nutritional support - This is not optional supportive care; it's essential therapy 3, 1, 5